THE KITASATO INSTITUTE Patent applications |
Patent application number | Title | Published |
20160122349 | MORPHINAN DERIVATIVE - The present invention relates to a morphinan derivative represented by the following general formula (I), wherein R | 05-05-2016 |
20150335610 | PDK4 INHIBITOR AND USE THEREOF - The purpose of the present invention is to provide a therapeutic agent or preventive agent for exacerbation of influenza, specifically to provide a novel pyruvate dehydrogenase kinase 4 (PDK4) inhibitor. The present invention relates to a PDK4 inhibitor, medical composition or cosmetic composition containing as the active ingredient a compound represented by any one of the following general formulas (I) through (III) and a pharmaceutically acceptable ester derivative thereof, or a pharmaceutically acceptable salt of the same. | 11-26-2015 |
20140343015 | MORPHINAN DERIVATIVE - A morphinan derivative represented by the following general formula (I) | 11-20-2014 |
20140206889 | NOVEL MANGROMICIN COMPOUND AND PRODUCTION METHOD THEREFOR | 07-24-2014 |
20140045778 | PEST CONTROL AGENTS - Disclosed is a composition for use as a pest control agent, comprising a compound represented by formula (I) or an agriculturally and horticulturally acceptable salt thereof as active ingredient and an agriculturally and horticulturally acceptable carrier: | 02-13-2014 |
20110195091 | Avian Influenza Virus Antigen, and Booster Immunization Method for Avian Influenza Vaccine in Combination with Mucosal Adjuvant Which is Effective Through Oral Administration - When ELISA antibody titer dropped in chickens intramuscularly inoculated with an oil vaccine, recombinant HA and NP antigens prepared using gene recombinant technology were orally administered in combination with synthetic oligo CpG as a mucosal adjuvant to the chickens. Even when the immune response induced with the oil vaccine was impaired, the antibody titer was re-induced by orally administering the recombinant HA and NP antigens, and synthetic CpG-ODN in combination. | 08-11-2011 |
20110184173 | Pyripyropene Derivatives Having An ACAT2-Inhibiting Activity - The present invention is a compound having the general formula (I), (II), or (III) or a pharmacologically acceptable salt, solvate, or hydrate thereof, and a pharmaceutical composition containing such a compound, or its pharmacologically acceptable ester, or other pharmacologically acceptable derivative thereof as an active ingredient. The compound has an excellent ACAT 2-inhibiting activity by a mechanism different from that of a statin drug and is useful as a therapeutic or prophylactic agent for obesity, adiposis, hyperlipidemia, hypercholesterolemia, disorder of lipid metabolism, and arteriosclerosis, as well as obesity-derived hyperlipidemia, hypercholesterolemia, disorder of lipid metabolism, arteriosclerosis, and hypertension. | 07-28-2011 |
20110021848 | WICKEROL AND METHOD FOR PRODUCING THE SAME - The present invention includes wickerol and a method for producing the wickerol. In the method for producing the wickerol, | 01-27-2011 |
20100267047 | Test Method on Feline Vaccinated with Feline Immunodeficiency Virus Vaccine, and Antigen for Use in the Test - Since FIV-vaccinated cats produce antibodies against FIV, distinguishing them from FIV-infected cats is difficult by serological diagnostic methods using FIV and FIV-derived substances. The present invention enables tests for determining the presence or absence of a FIV vaccination history in a cat by detecting antibodies that are produced as a result of vaccination of a cat with an FIV vaccine, but not as a result of FIV infection. Using the methods of the present invention, whether an anti-FIV antibody-positive cat is infected with FIV or has been vaccinated can be conveniently distinguished. | 10-21-2010 |
20100260803 | Bordetella Parapertussis Whole-Cell Vaccine Composition - An objective of the present invention is to provide a whole-cell bacterial vaccine composition for preventing whooping cough caused by | 10-14-2010 |
20100055038 | Methods for Predicting Effectiveness of Apheresis Therapy for Heart Failure - An objective of the present invention is to provide methods for predicting the effectiveness of apheresis therapy in the treatment of dilated cardiomyopathy. | 03-04-2010 |
20090093646 | NOVEL COMPOUND OF STEMPHONES AND PRODUCTION THEREOF - The present invention relates to novel compound of stemphones obtained by culturing microorganism belonging to genus | 04-09-2009 |
20090004227 | Peroral Vaccine Carrier System - The present invention provides a system in which a recombinant plant expressing a target peptide is orally administered to thereby achieve exertion of the function of the peptide, along with the genetically recombinant plant, and the present invention relates to a carrier system for oral administration of a target peptide by oral administration of a plant (potato) that expresses a target peptide by expressing for example a fused gene obtained by fusing the LRE1 gene coding for the immunogenic peptide LRE1 derived from the | 01-01-2009 |